Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial
Open accessThe DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Abstract
Background Several small studies suggest that the adjunctive use of anti-inflammatory agents might improve depressive symptoms in bipolar disorder. However, there are few well designed, appropriately powered clinical trials assessing the efficacy of these novel treatment strategies. We aimed to assess the efficacy of adjunctive minocycline or celecoxib in this setting.Methods This double-blind, 12-week, randomised, placebo-controlled trial was done in four outpatient psychiatric clinics in Pakistan. Eligible participants were adults (aged 18-65 years) with DSM-5 bipolar disorder (type I or II) and a major depressive episode. In a 2 × 2 factorial design, participants were randomly assigned (1:1:1:1) to receive either active minocycline plus active celecoxib, active minocycline plus placebo celecoxib, placebo minocycline plus active celecoxib, or placebo minocycline plus placebo celecoxib. The primary outcome was the mean change from baseline to week 12 in score on the 17-item Hamilton Depression Rating Scale (HAMD-17), assessed in all randomised participants (missing data were imputed and assumed to be missing at random). The trial was registered with ClinicalTrials.gov, NCT02703363.Findings 266 (17%) of 1542 patients assessed between May 1, 2016, and March 31, 2019, were randomly assigned to receive minocycline plus celecoxib (n=68), minocycline plus placebo (n=66), celecoxib plus placebo (n=66), or placebo plus placebo (n=66). From baseline to week 12, depressive symptoms as per HAMD-17 reduced in all four groups (from 24·5-25·2 to 11·3-12·8), but these reductions did not differ significantly between the groups. In terms of main effects, reductions in HAMD-17 did not differ for patients treated with minocycline (mean adjusted difference vs non-minocycline 1·48 [95% CI -0·41 to 3·36]; p=0·123) or for celecoxib (mean adjusted difference vs non-celecoxib -0·74 [-2·61 to 1·14]; p=0·443). Rates of serious adverse effects did not differ between groups (31 participants had a manic switch, two self-harmed, and one died in a motor vehicle accident).Interpretation We found no evidence that minocycline or celecoxib was superior to placebo for the treatment of bipolar depression. This large trial casts doubt on the potential therapeutic benefits of adjunctive anti-inflammatory drugs for the acute management of bipolar depression.Funding Stanley Medical Research Institute.
Overview
CoChat Summary
TL;DR
In a 12-week, double-blind, 2×2 factorial randomised placebo-controlled trial in Pakistan, adjunctive minocycline and celecoxib were not superior to placebo for bipolar depression. Depressive symptoms fell substantially in all four groups, but neither drug produced a significant advantage on the HAMD-17.
Key findings
- 266 (17%) of 1542 assessed patients were randomised: minocycline plus celecoxib (n=68), minocycline plus placebo (n=66), celecoxib plus placebo (n=66), and placebo plus placebo (n=66).
- HAMD-17 scores fell in all four groups from baseline to week 12 (from 24·5–25·2 to 11·3–12·8), with no significant between-group differences.
- Main effects were null: minocycline versus non-minocycline mean adjusted difference 1·48 (95% CI −0·41 to 3·36; p=0·123); celecoxib versus non-celecoxib −0·74 (−2·61 to 1·14; p=0·443).
- Serious adverse effects did not differ between groups; 31 participants had a manic switch, two self-harmed, and one died in a motor vehicle accident.
Methods
- Design: double-blind, 12-week, randomised, placebo-controlled trial with a 2×2 factorial design (1:1:1:1 allocation), conducted at four outpatient psychiatric clinics in Pakistan; registered as NCT02703363.
- Participants: adults aged 18–65 years with DSM-5 bipolar disorder (type I or II) and a major depressive episode, assessed between May 1, 2016, and March 31, 2019.
- Primary outcome: mean change from baseline to week 12 on the 17-item Hamilton Depression Rating Scale (HAMD-17), analysed in all randomised participants with missing data imputed and assumed missing at random.
Limitations
- The paper's stated limitations are not reported in the abstract provided.
- Evident from the text: the trial was conducted only in Pakistan, which may limit generalisability to other settings and populations.
- Evident from the text: all groups improved markedly (roughly halving HAMD-17 scores), indicating a large non-specific/placebo response that may have obscured any modest drug effect.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Rates of serious adverse effects did not differ between groups (31 participants had a manic switch, two self-harmed, and one died in a motor vehicle accident).”
plainn = 31- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or for celecoxib (mean adjusted difference vs non-celecoxib −0·74 [–2·61 to 1·14]; p=0·443)”
plainn = 1,542- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“From baseline to week 12, depressive symptoms as per HAMD-17 reduced in all four groups (from 24·5–25·2 to 11·3–12·8)”
plainstates a causen = 1,542- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but these reductions did not differ significantly between the groups”
plainn = 1,542- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“reductions in HAMD-17 did not differ for patients treated with minocycline (mean adjusted difference vs non-minocycline 1·48 [95% CI −0·41 to 3·36]; p=0·123)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
1 more claim
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 4
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, the results are inconsistent [90,91].”
From Peripheral immunity and risk of incident brain disorders: a prospective cohort study of 161,968 participants (2023) · doi:10.1038/s41398-023-02683-0 · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“trials in unselected or minimally enriched populations have reported no significant antidepressant benefit from anti-inflammatory interventions [63, 64], reinforcing the need for biomarker-stratified patient selection to demonstrate efficacy.”
From Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies (2026) · cites this paper as [64]
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
The clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed · Cited by 2,759
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Self-citationGeddes, J. R., & Miklowitz, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60857-0 · Cited by 848
Cited by
McIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047
Self-citationNovel and emerging treatments for major depression
Marwaha, S., Palmer, E., Suppes, T., Cons, E., Young, A. H., & Upthegrove, R. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 588
Self-citationNettis, M. A., Lombardo, G., Hastings, C., Zajkowska, Z., Mariani, N., Nikkheslat, N., Worrell, C., Enache, D., McLaughlin, A., Kose, M., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00948-6 · Cited by 235
Self-citationSolmi, M., Suresh Sharma, M., Osimo, E. F., Fornaro, M., Bortolato, B., Croatto, G., Miola, A., Vieta, E., Pariante, C. M., Smith, L., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.07.014 · Cited by 196
Self-citationDiagnosis and management of bipolar disorders
Goes, F. S. (2023) · BMJ · doi:10.1136/bmj-2022-073591 · Cited by 202
Metadata
- Authors
- Husain, M. I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Hodsoll, J., Ansari, M. A., Naqvi, H. A., Minhas, F. A., Carvalho, A. F., Meyer, J. H., Deakin, B., Mulsant, B. H., Husain, N., & Young, A. H.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- University of Manchester (GB)
- Pakistan Institute of Learning and Living (PK)
- King's College London (GB)
- Liaquat University of Medical & Health Sciences (PK)
- Dow University of Health Sciences (PK)
- Rawalpindi Medical University (PK)
- University of Toronto (CA)
- Corresponding author
- Husain, Muhammad Ishrat
- ORCID
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 7
- Issue
- 6
- Pages
- 515-527
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W3028537003
- Cited by
- 167
- References
- 43
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 26 · 2023: 34 · 2022: 32 · 2021: 30 · 2020: 10
- FWCI
- 19.34
- Type
- journal article
- Language
- en
- Open access
- green
- kclpure.kcl.ac.uk
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, cc-by-nc-nd)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- Patient-Centered Outcomes Research Institute
- King's College London
- Stanley Medical Research Institute (ID-15T 004)
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- Fondation Brain Canada
- Centre for Addiction and Mental Health Foundation
- National Institutes of Health
- National Institute for Health Research
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- minocycline, celecoxib, bipolar depression, adjunctive therapy, anti-inflammatory agents, major depressive episode, bipolar disorder, depressive symptoms, Hamilton Depression Rating Scale, adverse events, drug safety, factorial design, Pakistan, South Asia, low- and middle-income countries, treatment-resistant depression, mood stabilizers
- MeSH terms
- Celecoxib, Adult, Anti-Inflammatory Agents, Non-Steroidal, Anti-Bacterial Agents, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Minocycline, Pakistan, Placebos, Psychiatric Status Rating Scales, Case-Control Studies, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2215-0366(20)30138-3
- The paper
- Husain, M. I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Hodsoll, J., Ansari, M. A., Naqvi, H. A., Minhas, F. A., Carvalho, A. F., Meyer, J. H., Deakin, B., Mulsant, B. H., Husain, N., & Young, A. H. (2020). Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(20)30138-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.